First Beijing Investment Ltd disclosed a new position in Legend Biotech (LEGN 3.88%), acquiring 2,296,335 shares in the first quarter, with the estimated trade valued at $43.78 million based on average quarterly pricing, according to a May 13, 2026, SEC filing.
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
- Initiated new stake: 2,296,335 shares; estimated trade value $43.78 million (based on quarterly average price)
- Quarter-end position value at $41.54 million, representing a net valuation change that includes price movements
- Trade represented a 1.89% increase in 13F reportable assets under management
- Post-trade: 2,296,335 shares held, valued at $41.54 million
- Position accounts for 1.79% of 13F AUM, which places it outside the fund’s top five holdings
What happened
According to an SEC filing dated May 13, 2026, First Beijing Investment Ltd established a new stake in Legend Biotech, purchasing 2,296,335 shares. The estimated transaction value was $43.78 million, calculated using the average closing price for the first quarter. The quarter-end value of this position stood at $41.54 million, reflecting both purchase activity and share price movement during the period.
What else to know
- New position: stake represents 1.79% of 13F reportable assets under management as of March 31, 2026
- Top holdings after the filing:
- NASDAQ: PDD: $832.68 million (35.9% of AUM)
- NYSE: YMM: $747.01 million (32.2% of AUM)
- NYSE: EDU: $509.40 million (22.0% of AUM)
- NYSE: RLX: $132.29 million (5.7% of AUM)
- NASDAQ: KSPI: $32.17 million (1.4% of AUM)
- As of May 15, 2026, Legend Biotech shares were priced at $27.55, down 0.5% over the prior year, underperforming the S&P 500 by 25.7 percentage points
Company Overview
| Metric | Value |
|---|---|
| Price (as of market close 2026-05-15) | $27.55 |
| Market Capitalization | $5.08 billion |
| Revenue (TTM) | $1.14 billion |
| Net Income (TTM) | ($250.98 million) |
Company Snapshot
- Legend Biotech develops and commercializes novel cell therapies, including its lead CAR-T product candidate for multiple myeloma and a pipeline targeting various hematologic malignancies and solid tumors.
- The company generates revenue primarily through the development and licensing of its cell therapy portfolio, leveraging strategic collaborations such as its agreement with Janssen Biotech for ciltacabtagene autoleucel.
- Legend Biotech targets oncology patients, healthcare providers, and pharmaceutical partners in the United States, China, and international markets.
Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on advancing innovative cell therapies for cancer and related diseases. The company leverages proprietary CAR-T technologies and strategic partnerships to address high unmet medical needs in oncology. With a growing portfolio and international presence, Legend Biotech aims to establish a competitive position in the global biotechnology sector.
What this transaction means for investors
First Beijing runs a hyper-concentrated book — three names make up roughly 90% of its reported assets, all in Chinese tech and consumer. Adding Legend Biotech at 1.79% of AUM is a toe-dip into a different corner of the China ADR universe, not a conviction call. The stock had already given back meaningful ground before this position was opened, which is worth knowing, but the filing doesn’t tell you why First Beijing bought or what their target is. A small new position from a fund this concentrated says less than the same allocation would from a more diversified manager. If you’re trying to decide whether Legend Biotech belongs in your portfolio, the CAR-T pipeline and the Janssen partnership are the questions that matter — this 13F just tells you one institution got off the sidelines at a depressed price.
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Joint Stock Kaspi.kz and Legend Biotech. The Motley Fool has a disclosure policy.
